Collplant Biotechnologies Ltd Stock Price, News & Analysis

CollPlant Biotechnologies (Nasdaq: CLGN) announced its participation in the International Conference on Biofabrication 2025, scheduled for September 14-17, 2025, in Warsaw, Poland. The company will deliver two presentations: "rhCollagen Bioinks for Biofabrication" on September 16th during the Industrial Session, and "Mechanical Computational Modeling and Simulation of Biodegradable Implants" on September 17th.

The company will showcase its rhCollagen platform and biofabrication applications at an exhibition booth. CollPlant's rhCollagen-based bioinks are designed for 3D bioprinting applications in medical research, featuring controlled rheology, non-animal safety profile, biocompatibility, and tunable mechanical properties.

CollPlant Biotechnologies (NASDAQ: CLGN), a company focused on regenerative and aesthetics medicine using non-animal-derived recombinant human collagen technology, has announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference.

The conference will take place on September 8-9, 2025, at the Lotte New York Palace Hotel. Senior management will be available for one-on-one meetings with investors, which can be arranged through H.C. Wainwright representatives or via meetings@hcwco.com.

CollPlant Biotechnologies (NASDAQ:CLGN) reported Q2 2025 financial results and provided updates on its key programs. The company recorded revenues of $179,000 in Q2 2025, down from $249,000 in Q2 2024, with a net loss of $3.3 million. For the first half of 2025, revenues reached $2.2 million, primarily due to a $2 million milestone payment from AbbVie.

Key developments include advancing its photocurable dermal filler program toward clinical stage, progress in regenerative breast implants development with successful 3D bioprinting of 200cc commercial-size implants, and expansion of Vergenix™ STR distribution into new markets. The company strengthened its financial position through a $3.6 million registered direct offering and ended Q2 with $11.4 million in cash.

CollPlant also appointed Bowman Bagley as VP of Commercial North America and expanded its agreement with STEMCELL Technologies for broader use of its rhCollagen technology.

CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 20, 2025, before U.S. markets open. The company, known for its innovative non-animal-derived rhCollagen technology for tissue regeneration and medical aesthetics, will provide updates on its financial performance.

CollPlant Biotechnologies (NASDAQ:CLGN) has appointed Bowman Bagley as Vice President, Commercial North America in a newly created position. Bagley, who previously served as VP at Wasatch Biolabs and CEO at Advanced BioMatrix, will lead the company's commercial strategy and execution in North America.

The appointment aligns with CollPlant's growth strategy for its non-animal-derived recombinant human collagen (rhCollagen) technology. Bagley will oversee sales, marketing, logistics, and market expansion for CollPlant's rhCollagen-based products and platforms, particularly focusing on bioinks portfolio growth and research market sales.

Bagley brings extensive experience in collagen-based biomaterials, 3D bioprinting, and tissue engineering, along with a track record in sales, product development, and licensing. He holds a B.S. in Neuroscience and an MBA from the University of Utah.

CollPlant Biotechnologies (NASDAQ: CLGN) has expanded its partnership with STEMCELL Technologies to extend the use of CollPlant's proprietary rhCollagen beyond research applications into clinical development and commercial-scale manufacturing. The company's plant-derived, Type I recombinant human collagen technology is positioned as a safer, more sustainable alternative to animal-sourced materials. This expansion reflects market evolution and growing industry demand for ethically sourced, consistent materials in regenerative medicine, tissue regeneration, and medical aesthetics applications.

CollPlant Biotechnologies (CLGN) has secured a European patent allowance for its collagen-based formulations used in soft tissue fillers and implants. The patent, valid until 2041, covers injectable fillers and regenerative breast implant technology based on their proprietary recombinant human collagen (rhCollagen). The protected technology includes a 3D biocompatible and degradable soft tissue implant with a bioprinted scaffold and injectable filler. This development strengthens CollPlant's position in the aesthetic and reconstructive markets, with the injectable soft-tissue filler market valued at over $6 billion and the breast implant market estimated at over $3 billion.

CollPlant Biotechnologies (NASDAQ: CLGN) has announced a $3.6 million registered direct offering priced at-the-market, selling 1,200,002 ordinary shares at $3.00 per share. The company will also issue unregistered warrants to purchase up to 1,200,002 ordinary shares at a $3.00 exercise price in a concurrent private placement. The warrants will be exercisable immediately with a 3.5-year term. H.C. Wainwright & Co. is serving as the exclusive placement agent. The proceeds will support general corporate purposes, including collaboration with AbbVie on dermal filler development, working capital, and R&D programs. The offering is expected to close around June 2, 2025.

CollPlant Biotechnologies (NASDAQ: CLGN) reported Q1 2025 financial results and corporate updates. The company received a $2 million milestone payment from AbbVie in February 2025. Q1 revenues were $2.1 million, up from $98,000 in Q1 2024, with a net loss of $1.5 million. Cash position stood at $10.7 million as of March 31, 2025. The company continues advancing its regenerative breast implant program, with successful 3D bioprinting of 200cc commercial-size implants and encouraging preclinical results. CollPlant implemented a cost-cutting plan, reducing workforce by 20%, extending runway through Q2 2026. The company is also progressing with its photocurable dermal filler program and expanding distribution of Vergenix STR across Europe and Asia. Notable developments include new patents in Japan for rhCollagen curable BioInks and expansion of their intellectual property portfolio.